Registration Deadline:
Vanderbilt Contact:
More Information:
Explore other Industry Opportunities:
An animal health company is seeking novel vaccine candidates to protect against canine leptospirosis and/or leptospiruria. The company aims to improve on currently available vaccines, particularly those with immunity to one specific serovar, typically from inactivated bacteria. Novel vaccines should provide cross-protection against multiple leptospira serovars including L. pomona, L. canicola, L. icterohaemorrhagiae, L. grippotyphosa, L. bratislava, L. australis, L. copenhageni, and L. autumnalis.
Approaches of interest
- Vaccine candidates providing cross-protection against at least two of the listed serovars (more comprehensive protection is desirable)
- Recombinant or chimeric proteins (subunit), or multiple proteins that provide cross-protection in combination
- Vectored vaccines
- Modified-live vaccines
Out of scope:
- Killed (inactivated) vaccines
- Leptospira vaccine development in non-canine species, unless readily applicable to achieve protection in canines
Developmental stage of interest: Cross-protection should be demonstrated in hamster challenge model or equivalent small animal model. Validation in a canine model is desirable.
Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.